<?xml version="1.0" encoding="UTF-8"?>
<p id="par0095">For phase II, patients with the viral disease in question are invited to join the study, where they are administered the BSAAs at the ideal therapeutic doses. Phase III is the longest of the phases, and includes multiple levels of securities to the studies, such as the use of placebos and double-blinded studies, to ensure the data is as unbiased as possible. Upon completing phase III, depending on its performance and efficacy, BSAAs may end either being approved or dropped. The U.S Food and Drug Administration (FDA) estimates that only 25â€“30% BSAA candidates that enter phase III are approved for use in the public (
 <xref rid="bib0475" ref-type="bibr">U.S Food and Drug Administration, 2018</xref>). After approval and marketing of the drug, phase IV may be initiated to follow up on the use of the drug in public, to surveil for rare effects (
 <xref rid="bib0475" ref-type="bibr">U.S Food and Drug Administration, 2018</xref>, 
 <xref rid="bib0480" ref-type="bibr">Umscheid et al., 2011</xref>).
</p>
